Latest articles and price-sensitive announcements with AI sentiment classification.
Neurotech shares are on a roll, thanks partly to a bullish report from Canary Capital that sings the paediatric drug ... Read More The post Health Check: Neurotech shares surge on upbeat research report appeared first on Stockhead.
Are Neurotech's (ASX:NTI) Registration Plans Taking Hold? Kalkine Media
director_dealing announcement
_07_03_2026_03_50_21_133108.jpg&w=3840&q=65)
Neurotech International (ASX:NTI), a clinical-stage biopharmaceutical company specializing in paediatric neurological disorders, has released its annual report for the financial year ending 30 June 2026. The report reveals the launch of its Phase III clinical trial for Autism Spectrum Disorder, the US FDA’s Rare Paediatric Disease Designation for Rett Syndrome, and the introduction of an Australian Authorised Prescriber Program for its lead drug candidate NTI164. Key Highlights Phase III 'B...
other announcement
Has Neurotech International (ASX:NTI) reset its drug path? Kalkine Media
Highlights The local session is opening with several macro forces moving at the same time. For Neurotech International Ltd, the cannabis shares lens highlights regulatory compliance, product portfolio development, distribution efficiency and cash discipline. The day may reward clear execution and transparent communication over broad thematic enthusiasm. Global market signals turned less supportive before the Australian open, creating a session where company quality and sector exposure may mat...
other announcement
Highlights Neurotech International Limited (ASX:NTI) develops technology aimed at neurological health applications. Its early-stage status places it among the more closely watched names within Penny Stocks. Development milestones remain the clearest indicator of its ongoing progress. Early-stage technology developers carry a distinct risk and reward profile compared with established companies, and Neurotech International Limited (ASX:NTI) sits within that category through its work in neurolog...
Highlights Neurotech International enters the September spotlight as liquidity across smaller Australian companies remains selective. Higher bond yields, elevated energy prices and uneven sector leadership are creating a more demanding backdrop for emerging healthcare businesses. Neurotechs focus on cannabinoid-based therapies for neurological conditions keeps its clinical progress and corporate disclosures central to the market narrative. The Australian share market is entering another ...
Highlights A late-stage Australian study in autism spectrum disorder is recruiting across clinical sites. United States regulators cleared an investigational new drug submission for the lead candidate. The formulation is derived from a cultivar bred for very low tetrahydrocannabinol content. Neurotech International (ASX:NTI) is running a late-stage Australian trial of its cannabinoid-derived candidate in autism spectrum disorder while simultaneously opening a United States pathway, after clea...
other announcement
Highlights Neurotech International is developing a cannabinoid based medicine through paediatric clinical trials. Autism spectrum disorder has been the lead indication, with other neurological conditions behind it. The company sits apart from cultivation businesses because its value rests on clinical evidence. The latest local-market debate around cannabis stocks has brought Neurotech (ASX:NTI) back into view, with operating detail carrying more weight than broad sentiment. Neurotech Internat...
Neurotech International (ASX:NTI) Gains 17% as Autism Program Moves Toward US Study Kalkine
capital_raise announcement
other announcement
other announcement
Neurotech International Limited (ASX: NTI), a clinical-stage biopharmaceutical company focused on cannabinoid therapies for paediatric neurological disorders, has completed the issuance of ordinary fully paid shares without investor disclosure by utilising relief provisions under the Corporations Act. On 21 July 2026, the company confirmed compliance with Chapter 2M and related sections of the Act in a notice accompanying an Appendix 2A released the same day. Key Highlights Neurotech Internat...
Why Did Neurotech International (ASX:NTI) Shares Rise 12.5% Despite a Mixed One-Year Return? Kalkine
other announcement
Neurotech International (ASX:NTI) Rises 12.5% — What Is Driving the Paediatric Health Technology Stock? Kalkine
Neurotech International Ltd (ASX: NTI) Shares Rally as Investors Monitor Clinical Progress Kalkine
other announcement
other announcement
director_dealing announcement
other announcement
other announcement
other announcement
other announcement
other announcement
Stockhead
Google News
ASX
Kalkine
Small Caps